SCHEMBL5875745

SCHEMBL5875745

Nc1ncc(S(=O)(=O)c2ccc(NO)cc2)s1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.69
SLC6A3 Q01959 1/20 0.69
LOXL2 Q9Y4K0 8/20 0.43
LOX P28300 3/20 0.43
HTR6 P50406 1/20 0.38
KCNH2 Q12809 1/20 0.37
AOC3 Q16853 1/20 0.37
NAMPT P43490 2/20 0.37
GCK P35557 2/20 0.37
GCKR Q14397 2/20 0.37
QPCT Q16769 1/20 0.37
QPCTL Q9NXS2 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5875742 0.82 ADORA3 (0.47) ADORA3SLC6A3LOXL2LOXHTR6
Thiazolsulfone SCHEMBL152559 0.82 ADORA3 (1.00) ADORA3SLC6A3LOXL2LOXHTR6
SCHEMBL5875692 0.80 ADORA3 (0.76) ADORA3SLC6A3LOXL2LOXKCNH2
SCHEMBL19392345 0.79 ALDH1A1 (0.45) ADORA3SLC6A3LOXL2LOXALDH1A1
SCHEMBL1062382 0.79 ADORA3 (0.75) ADORA3SLC6A3LOXL2LOXHTR6
SCHEMBL5875599 0.77 ADORA3 (0.58) ADORA3SLC6A3LOXL2NAMPTALDH1A1
SCHEMBL1062638 0.76 ADORA3 (0.69) ADORA3SLC6A3ALDH1A1MEN1LMNA
SCHEMBL27736703 0.72 HTR6 (0.55) HTR6ALDH1A1MEN1LMNAMAPT
4-Amino-4'-Hydroxamine-Diphenylsulphone SCHEMBL29349839 0.71 HTR6 (0.67) HTR6ALDH1A1MEN1LMNAKMT2A
SCHEMBL9048270 0.71 ADORA3 (0.62) ADORA3SLC6A3LOXL2LOXKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP ADORA3 130/4885SLC6A3 1100/4885LOXL2 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.